ERBB2 and non-small cell lung carcinoma: Anti-HER2 TKIs failed to be effective in NSCLC; in phase II trials, dual EGFR/HER2 TKIs, such as afatinib, and irreversible pan-HER TKIs, like dacomitinib or neratinib, have shown little activity, with ORRs ranging from 0% to 19% [25].